tiprankstipranks
Vertex Pharmaceuticals (GB:0QZU)
LSE:0QZU
UK Market
0QZU
Vertex Pharmaceuticals
RESEARCH TOOLSreports

Vertex Pharmaceuticals (0QZU) Share Forecast & Price Target

9 Followers
See the Price Targets and Ratings of:

0QZU Analyst Ratings

Strong Buy
25Ratings
Strong Buy
20 Buy
4 Hold
1 Sell
Based on 25 analysts giving stock ratings to
Vertex
Pharmaceuticals
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

0QZU Stock 12 Month Forecast

Average Price Target

$573.38
▲(3.50% Upside)
Based on 25 Wall Street analysts offering 12 month price targets for Vertex Pharmaceuticals in the last 3 months. The average price target is $573.38 with a high forecast of $672.00 and a low forecast of $350.00. The average price target represents a 3.50% change from the last price of $553.99.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"349":"$349","430":"$430","511":"$511","592":"$592","673":"$673"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":672,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$672.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":573.3809523809523,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$573.38</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":350,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$350.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[349,430,511,592,673],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,548.7,558.1846153846154,567.6692307692308,577.1538461538462,586.6384615384616,596.123076923077,605.6076923076923,615.0923076923077,624.5769230769231,634.0615384615385,643.5461538461539,653.0307692307692,662.5153846153846,{"y":672,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,548.7,550.5985347985348,552.4970695970696,554.3956043956044,556.2941391941392,558.192673992674,560.0912087912088,561.9897435897435,563.8882783882783,565.7868131868131,567.6853479853479,569.5838827838827,571.4824175824175,{"y":573.3809523809523,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,548.7,533.4153846153847,518.1307692307693,502.84615384615387,487.5615384615385,472.2769230769231,456.9923076923077,441.70769230769235,426.4230769230769,411.13846153846157,395.8538461538461,380.5692307692308,365.2846153846154,{"y":350,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":392.09,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":403.01,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":426.47,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":426.95,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":455.85,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 47,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":472,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 50,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":488.32,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 56,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":447.6,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":424.28,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":437.07,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":497.47,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 50,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":476.76,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 59,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":548.7,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 52,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$672.00Average Price Target$573.38Lowest Price Target$350.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Citi Analyst forecast on GB:0QZU
Geoff Meacham
Citi
Citi
$585
Buy
5.60%
Upside
Reiterated
09/02/26
Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (NASDAQ: VRTX), Alumis Inc. (NASDAQ: ALMS) and Medtronic (NYSE: MDT)
Morgan Stanley Analyst forecast on GB:0QZU
Terence Flynn
Morgan Stanley
Morgan Stanley
$665
Buy
20.04%
Upside
Initiated
09/01/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
UBS Analyst forecast on GB:0QZU
Michael Yee
UBS
UBS
$585
Buy
5.60%
Upside
Assigned
08/20/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
BMO Capital Analyst forecast on GB:0QZU
Evan Seigerman
BMO Capital
BMO Capital
$600
Buy
8.31%
Upside
Reiterated
08/17/26
Vertex Pharmaceuticals (VRTX) Receives a Buy from BMO Capital
RBC Capital Analyst forecast on GB:0QZU
Brian Abrahams
RBC Capital
RBC Capital
$570
Buy
2.89%
Upside
Reiterated
08/12/26
Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (NASDAQ: VRTX), Brookdale Senior Living (NYSE: BKD) and Legend Biotech (NASDAQ: LEGN)
Jefferies Analyst forecast on GB:0QZU
Akash Tewari
Jefferies
Jefferies
$610→$633
Buy
14.26%
Upside
Reiterated
08/11/26
Jefferies Remains a Buy on Vertex Pharmaceuticals (VRTX)
Truist Financial Analyst forecast on GB:0QZU
Danielle Brill
Truist Financial
Truist Financial
―
Buy
―
Reiterated
08/11/26
Analysts Conflicted on These Healthcare Names: GE Healthcare Technologies Inc (NASDAQ: GEHC), Vertex Pharmaceuticals (NASDAQ: VRTX) and Agios Pharma (NASDAQ: AGIO)
Scotiabank Analyst forecast on GB:0QZU
Louise Chen
Scotiabank
Scotiabank
$558
Buy
0.72%
Upside
Reiterated
08/11/26
Scotiabank Remains a Buy on Vertex Pharmaceuticals (VRTX)
Bernstein Analyst forecast on GB:0QZU
Jeffrey Walch
Bernstein
Bernstein
$608
Buy
9.75%
Upside
Reiterated
08/11/26
Bernstein Sticks to Their Buy Rating for Vertex Pharmaceuticals (VRTX)
William Blair Analyst forecast on GB:0QZU
Myles Minter
William Blair
William Blair
―
Buy
―
Reiterated
08/10/26
Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (NASDAQ: VRTX) and MoonLake Immunotherapeutics (NASDAQ: MLTX)
Bank of America Securities Analyst forecast on GB:0QZU
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
$605→$672
Buy
21.30%
Upside
Reiterated
08/10/26
Analysts Offer Insights on Healthcare Companies: Jade Biosciences (NASDAQ: JBIO), Silence Therapeutics (NASDAQ: SLN) and Vertex Pharmaceuticals (NASDAQ: VRTX)
Stifel Nicolaus Analyst forecast on GB:0QZU
Paul Matteis
Stifel Nicolaus
Stifel Nicolaus
$66→$500
Hold
-9.75%
Downside
Reiterated
08/09/26
Wall Street Analysts Are Neutral on Top Healthcare Picks
Barclays Analyst forecast on GB:0QZU
Eliana Merle
Barclays
Barclays
$615→$617
Buy
11.37%
Upside
Reiterated
08/05/26
Barclays Sticks to Its Buy Rating for Vertex Pharmaceuticals (VRTX)
Maxim Group Analyst forecast on GB:0QZU
Naz Rahman
Maxim Group
Maxim Group
$575
Buy
3.79%
Upside
Reiterated
08/05/26
Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (NASDAQ: VRTX) and Q32 Bio (NASDAQ: QTTB)
H.C. Wainwright Analyst forecast on GB:0QZU
Andrew Fein
H.C. Wainwright
H.C. Wainwright
$641
Buy
15.71%
Upside
Reiterated
08/04/26
Analysts Are Bullish on These Healthcare Stocks: Vertex Pharmaceuticals (VRTX), Stoke Therapeutics (STOK)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Citi Analyst forecast on GB:0QZU
Geoff Meacham
Citi
Citi
$585
Buy
5.60%
Upside
Reiterated
09/02/26
Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (NASDAQ: VRTX), Alumis Inc. (NASDAQ: ALMS) and Medtronic (NYSE: MDT)
Morgan Stanley Analyst forecast on GB:0QZU
Terence Flynn
Morgan Stanley
Morgan Stanley
$665
Buy
20.04%
Upside
Initiated
09/01/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
UBS Analyst forecast on GB:0QZU
Michael Yee
UBS
UBS
$585
Buy
5.60%
Upside
Assigned
08/20/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
BMO Capital Analyst forecast on GB:0QZU
Evan Seigerman
BMO Capital
BMO Capital
$600
Buy
8.31%
Upside
Reiterated
08/17/26
Vertex Pharmaceuticals (VRTX) Receives a Buy from BMO Capital
RBC Capital Analyst forecast on GB:0QZU
Brian Abrahams
RBC Capital
RBC Capital
$570
Buy
2.89%
Upside
Reiterated
08/12/26
Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (NASDAQ: VRTX), Brookdale Senior Living (NYSE: BKD) and Legend Biotech (NASDAQ: LEGN)
Jefferies Analyst forecast on GB:0QZU
Akash Tewari
Jefferies
Jefferies
$610→$633
Buy
14.26%
Upside
Reiterated
08/11/26
Jefferies Remains a Buy on Vertex Pharmaceuticals (VRTX)
Truist Financial Analyst forecast on GB:0QZU
Danielle Brill
Truist Financial
Truist Financial
―
Buy
―
Reiterated
08/11/26
Analysts Conflicted on These Healthcare Names: GE Healthcare Technologies Inc (NASDAQ: GEHC), Vertex Pharmaceuticals (NASDAQ: VRTX) and Agios Pharma (NASDAQ: AGIO)
Scotiabank Analyst forecast on GB:0QZU
Louise Chen
Scotiabank
Scotiabank
$558
Buy
0.72%
Upside
Reiterated
08/11/26
Scotiabank Remains a Buy on Vertex Pharmaceuticals (VRTX)
Bernstein Analyst forecast on GB:0QZU
Jeffrey Walch
Bernstein
Bernstein
$608
Buy
9.75%
Upside
Reiterated
08/11/26
Bernstein Sticks to Their Buy Rating for Vertex Pharmaceuticals (VRTX)
William Blair Analyst forecast on GB:0QZU
Myles Minter
William Blair
William Blair
―
Buy
―
Reiterated
08/10/26
Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (NASDAQ: VRTX) and MoonLake Immunotherapeutics (NASDAQ: MLTX)
Bank of America Securities Analyst forecast on GB:0QZU
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
$605→$672
Buy
21.30%
Upside
Reiterated
08/10/26
Analysts Offer Insights on Healthcare Companies: Jade Biosciences (NASDAQ: JBIO), Silence Therapeutics (NASDAQ: SLN) and Vertex Pharmaceuticals (NASDAQ: VRTX)
Stifel Nicolaus Analyst forecast on GB:0QZU
Paul Matteis
Stifel Nicolaus
Stifel Nicolaus
$66→$500
Hold
-9.75%
Downside
Reiterated
08/09/26
Wall Street Analysts Are Neutral on Top Healthcare Picks
Barclays Analyst forecast on GB:0QZU
Eliana Merle
Barclays
Barclays
$615→$617
Buy
11.37%
Upside
Reiterated
08/05/26
Barclays Sticks to Its Buy Rating for Vertex Pharmaceuticals (VRTX)
Maxim Group Analyst forecast on GB:0QZU
Naz Rahman
Maxim Group
Maxim Group
$575
Buy
3.79%
Upside
Reiterated
08/05/26
Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (NASDAQ: VRTX) and Q32 Bio (NASDAQ: QTTB)
H.C. Wainwright Analyst forecast on GB:0QZU
Andrew Fein
H.C. Wainwright
H.C. Wainwright
$641
Buy
15.71%
Upside
Reiterated
08/04/26
Analysts Are Bullish on These Healthcare Stocks: Vertex Pharmaceuticals (VRTX), Stoke Therapeutics (STOK)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
PTGXProtagonist Therapeutics
AXGNAxoGen
ATECAlphatec Holdings
CABACabaletta Bio
ONCBeOne Medicines
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Vertex Pharmaceuticals

3 Months
Mohit BansalWells Fargo
Success Rate
26/34 ratings generated profit
76%
Average Return
+8.17%
Copying Mohit Bansal's trades and holding each position for 3 Months would result in 76.47% of your transactions generating a profit, with an average return of +8.17% per trade.
1 Year
Salveen RichterGoldman Sachs
Success Rate
18/23 ratings generated profit
78%
Average Return
+14.18%
Copying Salveen Richter's trades and holding each position for 1 Year would result in 78.26% of your transactions generating a profit, with an average return of +14.18% per trade.
2 Years
Tazeen AhmadBank of America Securities
Success Rate
17/17 ratings generated profit
100%
Average Return
+21.27%
Copying Tazeen Ahmad's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +21.27% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0QZU Analyst Recommendation Trends

Rating
May 26
Jun 26
Jul 26
Aug 26
Sep 26
Strong Buy
0
0
0
0
0
Buy
42
33
50
59
52
Hold
11
9
9
9
7
Sell
0
0
1
1
1
Strong Sell
0
0
0
0
0
total
53
42
60
69
60
In the current month, 0QZU has received 52 Buy Ratings, 7 Hold Ratings, and 1 Sell Ratings. 0QZU average Analyst price target in the past 3 months is 573.38.
Each month's total comprises the sum of three months' worth of ratings.

0QZU Financial Forecast

0QZU Earnings Forecast

Next quarter’s earnings estimate for 0QZU is $4.80 with a range of $3.68 to $5.18. The previous quarter’s EPS was $4.73. 0QZU beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 0QZU has Performed in-line its overall industry.
Next quarter’s earnings estimate for 0QZU is $4.80 with a range of $3.68 to $5.18. The previous quarter’s EPS was $4.73. 0QZU beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 0QZU has Performed in-line its overall industry.

0QZU Sales Forecast

Next quarter’s sales forecast for 0QZU is $3.41B with a range of $3.33B to $3.50B. The previous quarter’s sales results were $3.34B. 0QZU beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 0QZU has Performed in-line its overall industry.
Next quarter’s sales forecast for 0QZU is $3.41B with a range of $3.33B to $3.50B. The previous quarter’s sales results were $3.34B. 0QZU beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 0QZU has Performed in-line its overall industry.

0QZU Stock Forecast FAQ

What is GB:0QZU’s average 12-month price target, according to analysts?
Based on analyst ratings, Vertex Pharmaceuticals’s 12-month average price target is 573.38.
    What is GB:0QZU’s upside potential, based on the analysts’ average price target?
    Vertex Pharmaceuticals has 3.50% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Vertex Pharmaceuticals a Buy, Sell or Hold?
          Vertex Pharmaceuticals has a consensus rating of Strong Buy, which is based on 20 buy ratings, 4 hold ratings and 1 sell ratings.
            What is Vertex Pharmaceuticals’s share price target?
            The average share price target for Vertex Pharmaceuticals is 573.38. This is based on 25 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is $672.00 ,and the lowest forecast is $350.00. The average share price target represents 3.50% Increase from the current price of $553.99.
              What do analysts say about Vertex Pharmaceuticals?
              Vertex Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 25 Wall Streets Analysts.
                How can I buy shares of Vertex Pharmaceuticals?
                To buy shares of GB:0QZU, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.